
FDA conditionally accepts brand name CIFBEZY for Acurx's antibiotic ibezapolstat targeting C. difficile infection
Acurx Pharmaceuticals announced that the FDA has conditionally accepted the proprietary name CIFBEZY for its lead antibiotic candidate, ibezapolstat, which is being developed to treat and reduce recurrence of Clostridioides difficile infection (CDI)....

